Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
Ontology highlight
ABSTRACT: Pharmacokinetics, safety, and tolerability of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg were assessed in this phase 1, single-arm, open-label, single-dose study in fasted healthy male (n = 4) and female (n = 8) participants of Japanese heritage. Participants received a single dose of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg after an 8-hour fast, with safety assessments and blood samples for pharmacokinetic parameters collected through 72 hours after dosing. Geometric mean maximum plasma concentrations were 5.22 μg/mL (time to maximum concentration [tmax ], 1.01 hours) for abacavir, 4.13 μg/mL (tmax , 3.50 hours) for dolutegravir, and 3.35 μg/mL (tmax , 2.98 hours) for lamivudine. Geometric mean area under the concentration-time curve
SUBMITTER: Singh RP
PROVIDER: S-EPMC8456852 | biostudies-literature | 2021 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA